Skip to content
Home/Companies/MedTech/Prostatype Genomics
PG

Prostatype Genomics

MedTech·Sweden·Exited 2020·Held 7yr

Prostatype Genomics is a MedTech company, headquartered in Sweden.

Entry
2013
Hold
7yr
Exit
2020
Est. EV
–

Who owns Prostatype Genomics?

Prostatype Genomics was owned by Creathor Ventures through Creathor Venture Fund III (2012 vintage) from 2013 to 2020, exited via IPO.

Hand-verified · updated 2026-07-07

Creathor Ventures
Investor
Creathor Ventures
Creathor Venture Fund III · 2012 · VC

Key facts

HQSweden
SectorMedTech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2020

More from Creathor Venture Fund III

Other portfolio companies in the same fund.

Allthings Technologies
Active
SoftwareSwitzerland· 2017
Blueprint Genetics
Exited 2020
MedTechFinland· 2017
to
EchoRing (R3 Communications)
Active
Deep TechGermany· 2017
CryoTherapeutics
Active
MedTechBelgium· 2016
Digital Insurance Group (Knip)
Active
FintechSwitzerland· 2015
AYOXXA Biosystems
Active
MedTechGermany· 2014

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Aflo
Active
Clarendon Fund ManagersUnited Kingdom
Lattice Medical
Active
Finovam GestionFrance
QTAS
Active
OVNI CapitalGermany
Axomove
Active
Go CapitalFrance· 2026
Bioliberty
Active
Scottish National Investment BankUK· 2026
CertHub
Active
Cusp Capital PartnersGermany· 2026
Data refreshed weekly · Sourced from public filings